Erin Hertlein

Erin Kathleen Hertlein , PhD

Assistant Professor



COM IM Hematology/Oncology Division - 0593

Professional Summary

Dr. Hertlein completed her graduate and post-doctoral studies at The Ohio State University prior to transferring to the University of Cincinnati in August of 2021 as a faculty member in the Division of Hematology and Oncology. Dr. Hertlein’s studies focus on novel drug development and mechanistic understanding of the development of leukemia, primarily chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Current research programs in the group focus on BCL3, PTPN11, EZH2, BCL2 and DHODH, as well as several other new targets. In general, our research strives to understand 1) the mechanistic contribution of these aberrant proteins and signaling pathways on leukemia development, 2) therapeutic mechanisms of novel agents directed at these targets, 3) how these targets mediate transcriptional regulation and cellular differentiation and 4) the impact on the tumor microenvironment, and how bone marrow stromal cells (BMSCs) and tumor-associated immune cells can be manipulated to enhance anti-tumor responses. We use novel animal models of both CLL and AML to characterize how the microenvironment can be subverted to support tumor development which is pivotal to our understanding of cancer development and response to therapy.

Research Support

Investigators:Hertlein, Erin 08-01-2021 -12-31-2023 American Cancer Society Investigating the Role of BCL3 in Ibrutinib Resistant CLL Role:PI 792000 Active Type:Grant Level:National

Grant: #CA230759 Investigators:Byrd, John; Hertlein, Erin 09-30-2024 -09-29-2027 Department of the Army Medical Research Acquisition Activity Plasmacytoid dendritic cells (pDCs) as a Primary Node of Immune Suppression and Treatment Resistance in Acute Myeloid Leukemia Role:PI 1561794.00 Hold Level:Federal


Peer Reviewed Publications

Lucas, Christopher R; Halley, Patrick D; Chowdury, Amjad A; Harrington, Bonnie K; Beaver, Larry; Lapalombella, Rosa; Johnson, Amy J; Hertlein, Erin K; Phelps, Mitch A; Byrd, John C; Castro, Carlos E (2022. ) DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.Small (Weinheim an der Bergstrasse, Germany), , 18 (26 ) ,e2108063 More Information

Fobare, Sydney; Kohlschmidt, Jessica; Ozer, Hatice Gulcin; Mrózek, Krzysztof; Nicolet, Deedra; Mims, Alice S; Garzon, Ramiro; Blachly, James S; Orwick, Shelley; Carroll, Andrew J; Stone, Richard M; Wang, Eunice S; Kolitz, Jonathan E; Powell, Bayard L; Oakes, Christopher C; Eisfeld, Ann-Kathrin; Hertlein, Erin; Byrd, John C (2022. ) Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.Blood advances, , 6 (5 ) ,1371-1380 More Information

Goswami, Swagata; Mani, Rajeswaran; Nunes, Jessica; Chiang, Chi-Ling; Zapolnik, Kevan; Hu, Eileen; Frissora, Frank; Mo, Xiaokui; Walker, Logan A; Yan, Pearlly; Bundschuh, Ralf; Beaver, Larry; Devine, Raymond; Tsai, Yo-Ting; Ventura, Ann; Xie, Zhiliang; Chen, Min; Lapalombella, Rosa; Walker, Alison; Mims, Alice; Larkin, Karilyn; Grieselhuber, Nicole; Bennett, Chad; Phelps, Mitch; Hertlein, Erin; Behbehani, Gregory; Vasu, Sumithira; Byrd, John C; Muthusamy, Natarajan (2022. ) PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.Blood, , 139 (9 ) ,1340-1358 More Information

Miller, Cecelia R; Huang, Ying; Ruppert, Amy S; Labanowska, Jadwiga; Jaglowski, Samantha M; Maddocks, Kami J; Rogers, Kerry A; Bhat, Seema; Kittai, Adam S; Grever, Michael; Lapalombella, Rosa; Abruzzo, Lynne V; Heerema, Nyla A; Byrd, John C; Hertlein, Erin K; Woyach, Jennifer A (2021. ) Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.Leukemia, , 35 (11 ) ,3287-3290 More Information

Chen, Timothy L; Harrington, Bonnie; Truxall, Jean; Wasmuth, Ronni; Prouty, Alexander; Sloan, Shelby; Lehman, Amy M; Sampath, Deepa; Orlemans, Eric; Baiocchi, Robert A; Alinari, Lapo; Byrd, John C; Woyach, Jennifer A; Hertlein, Erin (2021. ) Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.Journal of hematology & oncology, , 14 (1 ) ,36 More Information

Jeon, Jae Yoon; Buelow, Daelynn R; Garrison, Dominique A; Niu, Mingshan; Eisenmann, Eric D; Huang, Kevin M; Zavorka Thomas, Megan E; Weber, Robert H; Whatcott, Clifford J; Warner, Steve L; Orwick, Shelley J; Carmichael, Bridget; Stahl, Emily; Brinton, Lindsey T; Lapalombella, Rosa; Blachly, James S; Hertlein, Erin; Byrd, John C; Bhatnagar, Bhavana; Baker, Sharyn D (2020. ) TP-0903 is active in models of drug-resistant acute myeloid leukemia.JCI insight, , 5 (23 ) , More Information

Elgamal, Ola A; Mehmood, Abeera; Jeon, Jae Yoon; Carmichael, Bridget; Lehman, Amy; Orwick, Shelley J; Truxall, Jean; Goettl, Virginia M; Wasmuth, Ronni; Tran, Minh; Mitchell, Shaneice; Lapalombella, Rosa; Eathiraj, Sudharshan; Schwartz, Brian; Stegmaier, Kimberly; Baker, Sharyn D; Hertlein, Erin; Byrd, John C (2020. ) Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.Journal of hematology & oncology, , 13 (1 ) ,8 More Information

Do, Priscilla; Beckwith, Kyle A; Cheney, Carolyn; Tran, Minh; Beaver, Larry; Griffin, Brittany G; Mo, Xiaokui; Liu, Yang; Lapalombella, Rosa; Hertlein, Erin; Muthusamy, Natarajan; Byrd, John C (2019. ) Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.Journal of immunology (Baltimore, Md. : 1950), , 202 (9 ) ,2806-2816 More Information

McWilliams, Emily M; Lucas, Christopher R; Chen, Timothy; Harrington, Bonnie K; Wasmuth, Ronni; Campbell, Amanda; Rogers, Kerry A; Cheney, Carolyn M; Mo, Xiaokui; Andritsos, Leslie A; Awan, Farrukh T; Woyach, Jennifer; Carson, William E; Butchar, Jonathan; Tridandapani, Susheela; Hertlein, Erin; Castro, Carlos E; Muthusamy, Natarajan; Byrd, John C (2019. ) Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.Blood advances, , 3 (3 ) ,447-460 More Information

Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A; Maddocks, Kami J; Labanowska, Jadwiga; Breidenbach, Heather; Lozanski, Gerard; Zhao, Weiqiang; Gordon, Amber L; Jones, Jeffrey A; Flynn, Joseph M; Jaglowski, Samantha M; Andritsos, Leslie A; Blum, Kristie A; T Awan, Farrukh; Rogers, Kerry A; Grever, Michael R; Johnson, Amy J; Abruzzo, Lynne V; Hertlein, Erin K; Blachly, James S; Woyach, Jennifer A; Byrd, John C (2017. ) Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.Blood advances, , 1 (19 ) ,1584-1588 More Information

Chen, Timothy L; Tran, Minh; Lakshmanan, Aparna; Harrington, Bonnie K; Gupta, Nikhil; Goettl, Virginia M; Lehman, Amy M; Trudeau, Stephen; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin (2017. ) NF-?B p50 (nfkb1) contributes to pathogenesis in the E?-TCL1 mouse model of chronic lymphocytic leukemia.Blood, , 130 (3 ) ,376-379 More Information

Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney; Chen, Timothy L; Liu, Chaomei; Lehman, Amy; Blachly, James S; Zhang, Xiaoli; Lucas, David M; Grever, Michael R; Tallman, Martin S; Flinn, Ian W; Rassenti, Laura Z; Kipps, Thomas J; Sampath, Deepa; Coombes, Kevin R; Hertlein, Erin K (2017. ) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.Oncotarget, , 8 (16 ) ,25942-25954 More Information

Maddocks, Kami; Hertlein, Erin; Chen, Timothy L; Wagner, Amy J; Ling, Yonghua; Flynn, Joseph; Phelps, Mitch; Johnson, Amy J; Byrd, John C; Jones, Jeffrey A (2016. ) A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.Leukemia & lymphoma, , 57 (9 ) ,2212-5 More Information

Browning, Rebekah L; Byrd, William H; Gupta, Nikhil; Jones, Jeffrey; Mo, Xiaokui; Hertlein, Erin; Yu, Lianbo; Muthusamy, Natarajan; Byrd, John C (2016. ) Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.Cancer immunology research, , 4 (8 ) ,698-707 More Information

Chen, Timothy L; Gupta, Nikhil; Lehman, Amy; Ruppert, Amy S; Yu, Lianbo; Oakes, Christopher C; Claus, Rainer; Plass, Christoph; Maddocks, Kami J; Andritsos, Leslie; Jones, Jeffery A; Lucas, David M; Johnson, Amy J; Byrd, John C; Hertlein, Erin (2016. ) Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia.Oncotarget, , 7 (19 ) ,28684-96 More Information

Tsai, Yo-Ting; Lozanski, Gerard; Lehman, Amy; Sass, Ellen J; Hertlein, Erin; Salunke, Santosh B; Chen, Ching-Shih; Grever, Michael R; Byrd, John C; Lucas, David M (2015. ) BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.Leukemia research, , More Information

Guinn, D; Ruppert, A S; Maddocks, K; Jaglowski, S; Gordon, A; Lin, T S; Larson, R; Marcucci, G; Hertlein, E; Woyach, J; Johnson, A J; Byrd, J C (2015. ) miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.Leukemia, , 29 (5 ) ,1210-3 More Information

Balatti, Veronica; Rizzotto, Lara; Miller, Cecelia; Palamarchuk, Alexey; Fadda, Paolo; Pandolfo, Rosantony; Rassenti, Laura Z; Hertlein, Erin; Ruppert, Amy S; Lozanski, Arletta; Lozanski, Gerard; Kipps, Thomas J; Byrd, John C; Croce, Carlo M; Pekarsky, Yuri (2015. ) TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America, , 112 (7 ) ,2169-74 More Information

Kämpjärvi, Kati; Järvinen, Tiina M; Heikkinen, Tuomas; Ruppert, Amy S; Senter, Leigha; Hoag, Kevin W; Dufva, Olli; Kontro, Mika; Rassenti, Laura; Hertlein, Erin; Kipps, Thomas J; Porkka, Kimmo; Byrd, John C; de la Chapelle, Albert; Vahteristo, Pia (2015. ) Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.Oncotarget, , 6 (3 ) ,1884-8 More Information

Liu, Ta-Ming; Ling, Yonghua; Woyach, Jennifer A; Beckwith, Kyle; Yeh, Yuh-Ying; Hertlein, Erin; Zhang, Xiaoli; Lehman, Amy; Awan, Farrukh; Jones, Jeffrey A; Andritsos, Leslie A; Maddocks, Kami; MacMurray, Jessica; Salunke, Santosh B; Chen, Ching-Shih; Phelps, Mitch A; Byrd, John C; Johnson, Amy J (2015. ) OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.Blood, , 125 (2 ) ,284-95 More Information

Hertlein, Erin; Beckwith, Kyle A; Lozanski, Gerard; Chen, Timothy L; Towns, William H; Johnson, Amy J; Lehman, Amy; Ruppert, Amy S; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M; Senter, Leigha; Croce, Carlo M; Symer, David E; de la Chapelle, Albert; Heerema, Nyla A; Byrd, John C (2013. ) Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.PloS one, , 8 (10 ) ,e76607 More Information

Justiniano, Steven E; Elavazhagan, Saranya; Fatehchand, Kavin; Shah, Prexy; Mehta, Payal; Roda, Julie M; Mo, Xiaokui; Cheney, Carolyn; Hertlein, Erin; Eubank, Timothy D; Marsh, Clay; Muthusamy, Natarajan; Butchar, Jonathan P; Byrd, John C; Tridandapani, Susheela (2013. ) Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.The Journal of biological chemistry, , 288 (37 ) ,26800-9 More Information

Gupta, Sneha V; Hertlein, Erin; Lu, Yanhui; Sass, Ellen J; Lapalombella, Rosa; Chen, Timothy L; Davis, Melanie E; Woyach, Jennifer A; Lehman, Amy; Jarjoura, David; Byrd, John C; Lucas, David M (2013. ) The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-?B response in chronic lymphocytic leukemia cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , 19 (9 ) ,2406-19 More Information

Mao, Yicheng; Triantafillou, Georgia; Hertlein, Erin; Towns, William; Stefanovski, Matthew; Mo, Xiaokui; Jarjoura, David; Phelps, Mitch; Marcucci, Guido; Lee, Ly James; Goldenberg, David M; Lee, Robert J; Byrd, John C; Muthusamy, Natarajan (2013. ) Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research, , 19 (2 ) ,347-56 More Information

Herman, Sarah E M; Gordon, Amber L; Hertlein, Erin; Ramanunni, Asha; Zhang, Xiaoli; Jaglowski, Samantha; Flynn, Joseph; Jones, Jeffrey; Blum, Kristie A; Buggy, Joseph J; Hamdy, Ahmed; Johnson, Amy J; Byrd, John C (2011. ) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Blood, , 117 (23 ) ,6287-96 More Information

Alinari, Lapo; Yu, Bo; Christian, Beth A; Yan, Fengting; Shin, Jungook; Lapalombella, Rosa; Hertlein, Erin; Lustberg, Mark E; Quinion, Carl; Zhang, Xiaoli; Lozanski, Gerard; Muthusamy, Natarajan; Prætorius-Ibba, Mette; O'Connor, Owen A; Goldenberg, David M; Byrd, John C; Blum, Kristie A; Baiocchi, Robert A (2011. ) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Blood, , 117 (17 ) ,4530-41 More Information

Hertlein, Erin; Triantafillou, Georgia; Sass, Ellen J; Hessler, Joshua D; Zhang, Xiaoli; Jarjoura, David; Lucas, David M; Muthusamy, Natarajan; Goldenberg, David M; Lee, Robert J; Byrd, John C (2010. ) Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.Blood, , 116 (14 ) ,2554-8 More Information

Hertlein, Erin; Wagner, Amy J; Jones, Jeffrey; Lin, Thomas S; Maddocks, Kami J; Towns, William H; Goettl, Virginia M; Zhang, Xiaoli; Jarjoura, David; Raymond, Chelsey A; West, Derek A; Croce, Carlo M; Byrd, John C; Johnson, Amy J (2010. ) 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.Blood, , 116 (1 ) ,45-53 More Information

Hertlein, Erin; Byrd, John C (2010. ) Signalling to drug resistance in CLL.Best practice & research. Clinical haematology, , 23 (1 ) ,121-31 More Information

Chen, Shih-Shih; Sherman, Mara H; Hertlein, Erin; Johnson, Amy J; Teitell, Michael A; Byrd, John C; Plass, Christoph (2009. ) Epigenetic alterations in a murine model for chronic lymphocytic leukemia.Cell cycle (Georgetown, Tex.), , 8 (22 ) ,3663-7 More Information

Chen, Shih-Shih; Raval, Aparna; Johnson, Amy J; Hertlein, Erin; Liu, Te-Hui; Jin, Victor X; Sherman, Mara H; Liu, Shu-Jun; Dawson, David W; Williams, Katie E; Lanasa, Mark; Liyanarachchi, Sandya; Lin, Thomas S; Marcucci, Guido; Pekarsky, Yuri; Davuluri, Ramana; Croce, Carlo M; Guttridge, Denis C; Teitell, Michael A; Byrd, John C; Plass, Christoph (2009. ) Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America, , 106 (32 ) ,13433-8 More Information

Wang, Huating; Hertlein, Erin; Bakkar, Nadine; Sun, Hao; Acharyya, Swarnali; Wang, Jingxin; Carathers, Micheal; Davuluri, Ramana; Guttridge, Denis C (2007. ) NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes.Molecular and cellular biology, , 27 (12 ) ,4374-87 More Information

Sarkar, Anasuya; Duncan, Michelle; Hart, Judy; Hertlein, Erin; Guttridge, Denis C; Wewers, Mark D (2006. ) ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions.Journal of immunology (Baltimore, Md. : 1950), , 176 (8 ) ,4979-86 More Information

Hertlein, Erin; Wang, Jingxin; Ladner, Katherine J; Bakkar, Nadine; Guttridge, Denis C (2005. ) RelA/p65 regulation of IkappaBbeta.Molecular and cellular biology, , 25 (12 ) ,4956-68 More Information

Bhatnagar, Bhavana; Kohlschmidt, Jessica; Orwick, Shelley J; Buelow, Daelynn R; Fobare, Sydney; Oakes, Christopher C; Kolitz, Jonathan E; Uy, Geoff; Stock, Wendy; Powell, Bayard L; Nicolet, Deedra; Hertlein, Erin K; Mrózek, Krzysztof; Blachly, James S; Eisfeld, Ann-Kathrin; Baker, Sharyn D; Byrd, John C (2023. ) Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.Blood advances, , 7 (16 ) ,4671-4675 More Information

Abdul-Aziz, Amina; Devine, Raymond D; Lyberger, Justin M; Chang, Hsiaochi; Kovacs, Amy; Lerma, James R; Rogers, Andrew M; Byrd, John C; Hertlein, Erin; Behbehani, Gregory K (2023. ) Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems.Cells, , 12 (16 ) , More Information

Eisenmann, Eric D; Stromatt, Jack C; Fobare, Sydney; Huang, Kevin M; Buelow, Daelynn R; Orwick, Shelley; Jeon, Jae Yoon; Weber, Robert H; Larsen, Bill; Mims, Alice S; Hertlein, Erin; Byrd, John C; Baker, Sharyn D (2022. ) TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion.Cancers, , 15 (1 ) , More Information

Hertlein, Erin (2014. ) A FOXy target in B-cell survival.Blood, , 124 (23 ) ,3340-1 More Information

Hertlein, Erin; Byrd, John C (2010. ) HLA-DR meets ERK.Blood, , 115 (25 ) ,5126-7 More Information

Hertlein, Erin; Byrd, John C (2008. ) CLL and activated NF-kappaB: living partnership.Blood, , 111 (9 ) ,4427 More Information